Meiqi Shao

No ORCID on file · 1 paper in corpus
2026
·doi:10.64898/2026.05.13.724829

The rapid advancement of mRNA therapeutics has imposed stringent requirements on both the quality and scalability of in vitro transcription (IVT) products. However, the accumulation of double-stranded RNA (dsRNA) byproducts and 3’-terminal …